Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–41 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Strip Clear all
Completed No phase listed Observational

ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma

NCT02135718
View directory record Official record
Conditions
Asthma
Interventions
ELLIPTA inhaler, Placebo Inhalation Aerosol (MDI)
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
Huntington Beach, California • Newport Beach, California • Vista, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Sep 24, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

A Pivotal Study to Assess the Effectiveness of Nasal Dilator (Breathe Right Nasal Strips)

NCT03549130
View directory record Official record
Conditions
Congestion, Nasal
Interventions
Breathe Right Tan (small/medium) nasal strips, Placebo nasal strip
Device · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Indianapolis, Indiana • Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 24, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Results available

DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)

NCT01868009
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ELLIPTA, DISKUS
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
17
States / cities
Jasper, Alabama • Riverside, California • Clearwater, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 24, 2026, 10:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Sunscreen Based on Bioadhesive Nanoparticles

NCT02668536
View directory record Official record
Conditions
Melanoma, UV Ray Skin Damage
Interventions
Standard Sunscreen, BNP
Drug · Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 24, 2026, 10:12 PM EDT
Completed Phase 4 Interventional Results available

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03474081
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/UMEC/VI, Tiotropium, Albuterol/salbutamol, Placebo to match FF/UMEC/VI, Placebo to match tiotropium, ELLIPTA inhaler, HANDIHALER, MDI
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
33
States / cities
Andalusia, Alabama • Huntington Beach, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 24, 2026, 10:12 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Lesion Progression After Icon Treatment in Young Adults

NCT01988337
View directory record Official record
Conditions
Caries, Salivary Function, Tooth Sensitivity
Interventions
Resin infiltration, Mock treatment
Device · Other
Lead sponsor
DMG Dental Material Gesellschaft mbH
Industry
Eligibility
19 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 24, 2026, 10:12 PM EDT
Completed Not applicable Interventional Results available

Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity

NCT02113579
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Experimental Mouth Rinse 12027-033, Placebo Mouth Rinse
Device · Other
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Fort Wayne, Indiana • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Sep 24, 2026, 10:12 PM EDT
Completed Phase 4 Interventional Results available

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

NCT02794480
View directory record Official record
Conditions
Asthma
Interventions
ELLIPTA DPI, GSK MDI, AZ MDI
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
20
States / cities
Huntington Beach, California • Aventura, Florida • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 24, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Results available

A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02152605
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Phoenix, Arizona • Upland, California • Clearwater, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 24, 2026, 10:12 PM EDT
Active, not recruiting Phase 1 Interventional

Study to Assess the Safety of DERMASEAL for Diabetic Foot Ulcers

NCT05586542
View directory record Official record
Conditions
Foot Ulcer, Diabetic
Interventions
DERMASEAL, Plasma Film, Standard of Care
Combination Product · Biological · Other
Lead sponsor
Vitruvian Medical Devices, Inc.
Industry
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Fresno, California • South Miami, Florida • Boardman, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 24, 2026, 10:12 PM EDT
Terminated Phase 3 Interventional Results available

Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

NCT05264506
View directory record Official record
Conditions
Contraception
Interventions
NOMAC-E2 COC
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
14 Years to 35 Years · Female only
Enrollment
3,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
103
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 24, 2026, 10:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial of Nano-hydroxyapatite-Containing Toothpastes for Relief of Dentin Hypersensitivity

NCT04590040
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Placebo, 15% nano-HAP toothpaste, 5% KNO3 toothpaste
Other · Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
20 Years to 80 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Sep 24, 2026, 10:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Evaluation of the Efficacy of Oral-B New Product Sensi-Stop on Dentinal Hypersensitivity

NCT02476032
View directory record Official record
Conditions
Tooth Sensitivity
Interventions
Prof applied oxalate, Self applied oxalate, Prof applied placebo
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2017 · Synced Sep 24, 2026, 10:12 PM EDT
Completed Phase 4 Interventional Results available

Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02786927
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA device, Placebo capsules for use in HANDIHALER device, Inhaler Preference Questionnaire Version 1, Inhaler Preference Questionnaire Version 2
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
22
States / cities
Glendale, Arizona • Clearwater, Florida • Orlando, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Sep 24, 2026, 10:12 PM EDT
Completed Phase 2 Interventional Results available

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

NCT03012061
View directory record Official record
Conditions
Asthma
Interventions
Placebo, UMEC, Fluticasone Furoate, Albuterol/salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
19
States / cities
Tempe, Arizona • Rolling Hills Estates, California • Colorado Springs, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Sep 24, 2026, 10:12 PM EDT
Completed Phase 4 Interventional Results available

Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects

NCT02586493
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, Questionnaire
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Jasper, Alabama • Clearwater, Florida • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 24, 2026, 10:12 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice

NCT07215767
View directory record Official record
Conditions
Dentin Hypersensitivity
Interventions
Stannous fluoride and Potassium nitrate Dentifrice, Stannous fluoride Dentifrice, Potassium nitrate Dentifrice, Vehicle Dentifrice
Drug
Lead sponsor
HALEON
Industry
Eligibility
12 Years to 65 Years
Enrollment
688 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Melbourne, Florida • Fort Wayne, Indiana • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 24, 2026, 10:12 PM EDT